MedTrace Logo

Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus

NCT04697485 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-05-10

No results posted yet for this study

Summary

This is a single-center, non-randomzied pilot study investigating a combination of targeted therapies as possible treatment for heart failure with preserved ejection fraction (HFpEF).

The study interviention is a Low-Dose, Triple Polydiuretic Therapy (LDTPT, or polydiuretic) including loop diuretic (bumetanide), mineralocorticoid receptor antagonist (eplerenone), and Sodium-glucose co-transporter 2 inhibitors (SGLT2i) therapy (dapaglifozin).

Conditions

Interventions

DRUG

Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg

Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of: * Loop diuretic (bumetanide 0.5 mg) * Mineralocorticoid receptor antagonist (eplerenone 25 mg) * Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg

Sponsors & Collaborators

Principal Investigators

  • Sadiya Khan, MD · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-08
Primary Completion
2022-01-01
Completion
2022-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04697485 on ClinicalTrials.gov